RxDoctor Payments Data

Jennifer Burr

Acute Care · New York, NYNPI 1528290988

Payments from drug & device makers

$1,973in general payments, 2019–2025

Across 108 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$534
  • Novartis$297
  • Boehringer Ingelheim$296
  • Amgen$156
  • Esperion Therapeutics, Inc.$74
  • Bridgebio Pharma, Inc.$71
  • plus $545 from 12 others

What the payments were for

  • Food & beverage$1,973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,973 in reported general payments places this provider in the 85th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$15,306
Medicare patients
158
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$345,834
EntrestoSacubitril/Valsartan125$185,937
JardianceEmpagliflozin94$104,363
XareltoRivaroxaban86$89,967
FarxigaDapagliflozin Propanediol50$53,486
Repatha SureclickEvolocumab56$47,105
OzempicSemaglutide16$15,813
Repatha SyringeEvolocumab17$11,316
MultaqDronedarone Hcl13$9,969
Metoprolol Succinate422$7,657
Ranolazine ErRanolazine31$4,879
Atorvastatin Calcium362$4,502
Rosuvastatin Calcium238$3,578
Ezetimibe147$3,274
Amiodarone Hcl41$2,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$345,834297 claims
NovartisEntresto$297$185,937125 claims
Boehringer IngelheimJardiance$296$104,36394 claims
Johnson & JohnsonXarelto$71$89,96786 claims
AstraZenecaFarxiga$58$53,48650 claims
Novo NordiskOzempic$54$15,81316 claims
Sanofi-aventis U.S. LLCMultaq$48$9,96913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 980 acute care providers in New York.

Other acute care in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →